{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T06:23:57Z","timestamp":1787207037058,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is no longer described through a single diagnostic vocabulary. Clinical criteria, prodromal probability models, and biological research classifications now operate in parallel after the 2024 NSD-ISS and SynNeurGe proposals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To clarify how major PD criteria and research frameworks have justified diagnostic change and redistributed the roles of clinical signs, biomarkers, genetics, and prodromal markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a targeted document-based qualitative content analysis of eight purposively selected landmark PD criteria or criteria-adjacent framework documents, with the 1988 UK Brain Bank\/Lewy body source retained as a historical lineage anchor. Document-declared aims and perceived diagnostic problems were coded with a prespecified framework, and twelve diagnostic elements were assigned interpretative ordinal scores according to their document-specific textual roles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within the selected corpus, stated priorities shifted from clinicopathological specificity, standardization, and differential diagnosis toward early identification, biomarker integration, staging\/subtyping, and trial readiness. Diagnostic-element roles moved from motor signs, exclusions, and dopaminergic response toward RBD\/olfaction in prodromal probability frameworks and toward \u03b1-synuclein SAA, dopaminergic imaging, and genetics in 2024 biological research frameworks. The analyzed documents indicated materially different 2024 architectures: NSD-ISS emphasized biological definition and integrated staging, whereas SynNeurGe used a multidimensional S\/N\/G structure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our analysis suggests that contemporary PD classification can be understood as a layered architecture rather than a simple replacement sequence. Clinical criteria remain necessary for care, prodromal criteria support early-risk research, and biological frameworks require longitudinal, pathological, technical, ethical, and global-access validation before clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1935021","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:28:52Z","timestamp":1787203732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Layered classification in Parkinson\u2019s disease: a content analysis of clinical, prodromal, and biological criteria evolution"],"prefix":"10.3389","volume":"18","author":[{"given":"Aishanjiang","family":"Yusufujiang","sequence":"first","affiliation":[{"name":"Department of Neurology, People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi","place":["Xinjiang, China"]},{"name":"Xinjiang Clinical Research Center for Stroke and Rare Neurological Disease, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Neurology, People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi","place":["Xinjiang, China"]},{"name":"Xinjiang Clinical Research Center for Stroke and Rare Neurological Disease, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi","place":["Xinjiang, China"]},{"name":"Xinjiang Clinical Research Center for Stroke and Rare Neurological Disease, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s1474-4422(25)00194-2","article-title":"\u03b1-synuclein biomarker assays: Bridging research and patient care.","volume":"24","author":"Agin-Liebes","year":"2025","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","article-title":"Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden.","volume":"147","author":"Bentivenga","year":"2024","journal-title":"Acta Neuropathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/mds.29683","article-title":"A statement of the MDS on biological definition, staging, and classification of Parkinson\u2019s disease.","volume":"39","author":"Cardoso","year":"2023","journal-title":"Mov. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41419-025-08076-z","article-title":"Are we ready for a biological diagnosis of Parkinson\u2019s Disease?","volume":"16","author":"Cimmino","year":"2025","journal-title":"Cell Death Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e210279","DOI":"10.1212\/wnl.0000000000210279","article-title":"\u03b1-Synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease.","volume":"104","author":"Coughlin","year":"2025","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/ana.27190","article-title":"Validating the accuracy of Parkinson\u2019s disease clinical diagnosis: A UK brain bank case\u2013control study.","volume":"97","author":"di Biase","year":"2025","journal-title":"Ann. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/s1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer\u2019s disease: Revising the NINCDS\u2013ADRDA criteria.","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/nejm198506203122504","article-title":"The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.","volume":"312","author":"Feinstein","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"105807","DOI":"10.1016\/j.parkreldis.2023.105807","article-title":"\u03b1-Synuclein seed amplification assay as a diagnostic tool for Parkinsonian disorders.","volume":"117","author":"Fernandes Gomes","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","article-title":"Diagnostic criteria for parkinson disease.","volume":"56","author":"Gelb","year":"1999","journal-title":"Arch. Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease.","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"\u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid\u2014A systematic review and meta-analysis.","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: The SynNeurGe research diagnostic criteria.","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/1877718x241298194","article-title":"SynNeurGe: The road ahead for a biological definition of Parkinson\u2019s disease.","volume":"15","author":"H\u00f6glinger","year":"2024","journal-title":"J. Parkinson\u2019s Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis.","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual. Health Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases.","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"B18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: Clinical features and diagnosis.","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/mds.30007","article-title":"International Parkinson and Movement Disorder Society viewpoint on biological frameworks of Parkinson\u2019s disease: Current status and future directions.","volume":"39","author":"Kalia","year":"2024","journal-title":"Mov. Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson progression marker initiative (PPMI).","volume":"95","author":"Marek","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fneur.2018.00156","article-title":"Diagnostic criteria for Parkinson\u2019s disease: From James Parkinson to the concept of prodromal disease.","volume":"9","author":"Marsili","year":"2018","journal-title":"Front. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"105925","DOI":"10.1016\/j.ebiom.2025.105925","article-title":"\u03b1-Synuclein seed amplification assay positivity beyond synucleinopathies. eBioMedicine.","author":"Martinez-Valbuena","year":"2025"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2703114","DOI":"10.1155\/padi\/2703114","article-title":"Towards a biologically defined diagnosis: Incorporating pathophysiological measures Into Parkinson\u2019s disease clinical criteria.","volume":"2026","author":"McNamara","year":"2026","journal-title":"Parkinson\u2019s Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/s1474-4422(25)00157-7","article-title":"Diagnostic and prognostic value of \u03b1-synuclein seed amplification assay kinetic measures in Parkinson\u2019s disease: A longitudinal cohort study.","volume":"24","author":"Orr\u00fa","year":"2025","journal-title":"Lancet Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/mds.27362","article-title":"Validation of the MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"33","author":"Postuma","year":"2018","journal-title":"Mov. Disord."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-03013-y","article-title":"Revisiting Parkinson\u2019s disease definition and classification: insights from two emerging biological frameworks.","author":"Reyes","year":"2025","journal-title":"J. Neural Transm."},{"key":"B28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: A cross-sectional study.","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/s1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: Towards an integrated staging system for research.","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s00415-025-12978-5","article-title":"Skin \u03b1-synuclein assays in diagnosing Parkinson\u2019s disease: A systematic review and meta-analysis.","volume":"272","author":"Zhao","year":"2025","journal-title":"J. Neurol."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1935021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:28:53Z","timestamp":1787203733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1935021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":30,"alternative-id":["10.3389\/fnagi.2026.1935021"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1935021","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1935021"}}